Floatz logo

Ningetinib

Advanced NSCLC

Sunshine Lake Pharma Co., Ltd.Small moleculePhase 2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

1205 Active assets in the Advanced NSCLC cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

Ningetinib is also rated in:

hepatocellular carcinomaDormant
C
Indicative ·
33 / 100
View asset →
renal cell carcinomaDormant
C
Indicative ·
33 / 100
View asset →
acute myeloid leukemiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →